<DOC>
	<DOCNO>NCT02810600</DOCNO>
	<brief_summary>Phase-II , prospective , open label , control group assess safety 68Ga-DOTA-TATE injection patient suspect diagnosed tumor express somatostatin receptor . Each include patient receive administer dose 50 mcg less peptide ( DOTA-TATE ) range activity 100 - 200 MBq 68Ga-DOTA-TATE . The efficacy 68Ga-DOTA-TATE assessing kind tumor prove numerous study .</brief_summary>
	<brief_title>Study Measure Safety 68Ga-DOTA-TATE PET/CT Diagnosis Tumors Expressing Somatostatin Receptors</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>1 . Patients suspect proven tumor express Somatostatin receptor 2 . Informed consent patient ( parent patient less 18 year age ) 1 . Pregnancy ( confirm ) . In case diagnostic procedure patient may pregnant , clinical decision necessary consider benefit possible harm carrying procedure . 2 . Patient refusal participate . 3 . Impossibility tolerate decubitus position 25 minute 4 . Prior allergic reaction DOTATATE somatostatin analog</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>